InterCure acquires leading cannabis company ISHI, gaining access to premium American brands and advanced cultivation technologies. This move aligns with the Trump administration’s exploration of cannabis rescheduling, offering international operators like InterCure unprecedented opportunities in the evolving U.S. cannabis landscape. The acquisition includes exclusive partnerships with top U.S. cannabis brands like The Flowery, providing InterCure with award-winning genetics and operational technologies. The transaction structure involves a two-phase acquisition of ISHI, with management integration and employee transition. Expected to close in Q1 2026, subject to regulatory approvals, this acquisition positions InterCure for significant global expansion and value creation.

InterCure CEO, Alexander Rabinovich, views the acquisition as a major milestone in the global expansion strategy, offering access to premium American cannabis genetics and operational technologies. ISHI CEO, Omer Layani, sees the acquisition as a culmination of years building relationships with top U.S. cannabis brands, now scalable internationally. The Flowery CEO, Elad Kohen, emphasizes the shared partnership values and the opportunity to expand into new markets. The transaction remains subject to customary closing conditions and regulatory approvals.

InterCure Ltd. (dba Canndoc) is the leading cannabis company outside of North America, leveraging a high-margin seed-to-sale model for global market leadership. Forward-looking statements highlight the potential for value creation and growth in the evolving U.S. cannabis landscape. For more information, visit: https://www.intercure.co.

Read more at GlobeNewswire: InterCure Announces Strategic Acquisition of ISHI,